MedTrace Logo

Evaluation of Metabolomic Analysis in Early Diagnosis of ALS

NCT01962311 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2019-07-17

No results posted yet for this study

Summary

This project is expected to answer the question of interest assays of metabolites in the CSF as a tool for early diagnosis and should show whether it is possible or not to use such markers in the blood or urine. These studies should also help shed light on the pathophysiological original early clinical disease. While ALS appears to be more a clinical syndrome that pathophysiological entity unique metabolic abnormalities identified could help identify mechanisms disrupted in which therapeutic interventions will be possible.

Conditions

Interventions

PROCEDURE

lumbar puncture

lumbar puncture at enrollment in study

Sponsors & Collaborators

  • University Hospital, Tours

    lead OTHER

Principal Investigators

  • Christian ANDRES, MD-PHD · University Hospital TOURS and INSERM U930

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2017-02-28
Completion
2018-02-28

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01962311 on ClinicalTrials.gov